

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5317563

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TIEN LEE	04/22/2016
HANS G. KLINGEMANN	04/22/2016
BARRY J. SIMON	03/30/2016
LAURENT BOISSEL	04/22/2016
RECEIVING PARTY DATA	
Name:	NANTKWEST, INC.
Street Address:	9920 JEFFERSON BLVD.
City:	CULVER CITY
State/Country:	CALIFORNIA
Postal Code:	90232
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15529848
CORRESPONDENCE DATA	
Fax Number:	(415)576-0300
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	sguevara@kilpatricktownsend.com
Correspondent Name:	JEAN M. LOCKYER
Address Line 1:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 2:	1100 PEACHTREE STREET, SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	099083-1050737- 2710US
NAME OF SUBMITTER:	SVETLANA GUEVARA
SIGNATURE:	/Svetlana Guevara/
DATE SIGNED:	01/09/2019
Total Attachments: 3	
source=Signed Assignment_Inventors to NantKwest (from PCT)#page1.tif	
source=Signed Assignment_Inventors to NantKwest (from PCT)#page2.tif	
source=Signed Assignment_Inventors to NantKwest (from PCT)#page3.tif	

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a PCT patent application entitled "GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER" which was filed with the U.S. Receiving Office on March 25, 2016 and assigned international application no. PCT/US2016/024318.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to sell, assign, transfer, and convey, and hereby do sell, assign, transfer, and convey, to **NantKwest, Inc.**, having a principal place of business at 9920 Jefferson Blvd., Culver City, CA 90232 ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, any application based in whole or in part upon the above-referenced patent application, including, without limitation, any application that is a provisional, non-provisional, design, divisional, continuation, continuation-in-part, reissue, reexamination, or non-U.S. patent application based in whole or in part on the above-referenced patent application, and the right to claim priority to the above-referenced patent application; and
 - (c) any patent (including, without limitation, any U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, continuations, continuations-in-part, divisionals, reissues and reexaminations) that is granted or issued upon, or that claims priority to, any and all applications under (b) of this paragraph or that discloses or claims intellectual property under (a) of this paragraph, in whole or in part.
2. Authorize and request the Commissioner of Patents or any other agency, U.S. or non-U.S., to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents under paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths, and petitions, and, at the Assignee's expense, perform any acts

ASSIGNMENT

International Application No. PCT/US2016/024318

Page 2 of 2

that are necessary in connection with prosecution of patent application(s) or intellectual property under paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Warrant and represent that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

1)

Signature: _____

Tien Lee

Date: _____

04/22/2016

2)

Signature: _____

Hans G. Klingemann

Date: _____

3)

Signature: _____

Barry J. Simon

Date: _____

4)

Signature: _____

Laurent Boissel

Date: _____

Assignee hereby accepts this Assignment

Signature: _____

Dated: _____

Name: _____

Title: _____

68317741V.1

ASSIGNMENT

International Application No. PCT/US2016/024318

Page 2 of 2

that are necessary in connection with prosecution of patent application(s) or intellectual property under paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.

4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Warrant and represent that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

- 1) Signature: _____ Date: _____
Tien Lee
- 2) Signature: [Signature] Date: 4/22/16
Hans G. Klingemann
- 3) Signature: [Signature] Date: 3/30/16
Barry J. Simon
- 4) Signature: [Signature] Date: 4/22/16
Laurent Boissel

Assignee hereby accepts this Assignment

Signature: [Signature] Dated: May 4, 2016
Name: Patrick Spon-Shiong
Title: Chief Executive Officer

68317741V.1